Non-Sponsored
Advertisement
Guest contributor Charles Gaulin, MBBS, outlines important updates on the first-line treatment of TP53-mutated MCL.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
Linvoseltamab earns FDA nod for RRMM with 70% ORR, monthly dosing, and lower CRS than other bispecifics.
Ruxolitinib shows durable benefit and long-term safety in steroid-refractory chronic GVHD, REACH3 finds.
The model estimates patients' 2-year progression-free survival using patient information routinely recorded in the clinic.
SGR-1505 has shown promising efficacy and safety in an ongoing, phase 1 dose-escalation study.
No new safety signals were observed in this phase 3 trial which compared the combination with placebo plus azacitidine.
Revumenib has received FDA Priority Review with a Prescription Drug User Fee Act target action date of October 25, 2025.
Pirtobrutinib, CAR T, and bispecifics are reshaping CLL care for high-risk, relapsed patients with limited options.
FDA approves tafasitamab plus R2 for relapsed FL, showing 57% reduced risk of progression in phase 3 inMIND trial.
TAG shows promise as frontline therapy in BPDCN, minimizing toxicity and supporting safer stem cell transplant.
The approval of tafasitamab-cxix in combination with rituximab and lenalidomide was based on the phase 3 inMIND trial.
SENTI-202, a first-in-class, off-the-shelf, logic-gated CAR-NK cell therapy, is currently being evaluated in a phase 1 trial.
Blood Cancers Today editors Krina Patel and Rahul Banerjee reflect on paradigm-shifting myeloma research from ASCO.
Vinayak (Vinay) Prasad, MD, MPH, has been appointed director of the FDA Center for Biologic Evaluation and Research.
Dr. Bhatnagar shared her research interests on rural disparities in AML and her experience working in a community setting.
FDA roadmap explores AI to predict toxicity, cut animal testing, and speed drug development with chip tech.
The advent of AI technologies such as machine learning has opened new avenues for predicting adverse drug reactions.
A U.S. claims database study revealed how clinicians are administering elranatamab therapy in the real-world setting.
The agent, nuvisertib, previously received Orphan Drug Designation from the FDA for this indication in May 2022.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.